Literature DB >> 10888626

Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function.

R Mahieux1, C A Pise-Masison, P F Lambert, C Nicot, L De Marchis, A Gessain, P Green, W Hall, J N Brady.   

Abstract

We have analyzed the functional activity of the p53 tumor suppressor in human T-cell lymphotropic virus type 2 (HTLV-2)-transformed cells. Abundant levels of the p53 protein were detected in both HTLV-2A and -2B virus-infected cell lines. The p53 was functionally inactive, however, both in transient-transfection assays using a p53 reporter plasmid and in induction of p53-responsive genes in response to gamma irradiation. We further investigated HTLV-2A Tax and HTLV-2B Tax effects on p53 activity. Interestingly, although Tax-2A and -2B inactivate p53, the Tax-2A protein appears to inhibit p53 function less efficiently than either Tax-1 or Tax-2B. In transient-cotransfection assays, Tax-1 and Tax-2B inactivated p53 by 80%, while Tax2A reduced p53 activity by 20%. In addition, Tax-2A does not increase the steady-state level of cellular p53 as well as Tax-1 or -2B does in the same assays. Cotransfection assays demonstrated that Tax-2A could efficiently transactivate CREB-responsive promoters to the same level as Tax-1 and Tax-2B, indicating that the protein was functional. This report provides evidence of the first functional difference between the HTLV-2A and -2B subtypes. This comparison of the action of HTLV-1 and HTLV-2 Tax proteins on p53 function will provide important insights into the mechanism of HTLV transformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888626      PMCID: PMC112204          DOI: 10.1128/jvi.74.15.6866-6874.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy.

Authors:  M Cavrois; I Leclercq; O Gout; A Gessain; S Wain-Hobson; E Wattel
Journal:  Oncogene       Date:  1998-07-09       Impact factor: 9.867

2.  DNA damage activates p53 through a phosphorylation-acetylation cascade.

Authors:  K Sakaguchi; J E Herrera; S Saito; T Miki; M Bustin; A Vassilev; C W Anderson; E Appella
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

3.  African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies.

Authors:  A M Vandamme; M Salemi; M Van Brussel; H F Liu; K Van Laethem; M Van Ranst; L Michels; J Desmyter; P Goubau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Estimation of rate of incidence of ATL among ATLV (HTLV-I) carriers in Kyushu, Japan.

Authors:  K Tajima; T Kuroishi
Journal:  Jpn J Clin Oncol       Date:  1985-06       Impact factor: 3.019

5.  HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes.

Authors:  J D Rosenblatt; A J Cann; D J Slamon; I S Smalberg; N P Shah; J Fujii; W Wachsman; I S Chen
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

6.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

7.  Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells.

Authors:  C A Pise-Masison; M Radonovich; K Sakaguchi; E Appella; J N Brady
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation.

Authors:  A J Cann; J D Rosenblatt; W Wachsman; N P Shah; I S Chen
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

9.  The x gene is essential for HTLV replication.

Authors:  I S Chen; D J Slamon; J D Rosenblatt; N P Shah; S G Quan; W Wachsman
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  26 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 2.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

3.  Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.

Authors:  Han Yin; Priya Kannian; Nathan Dissinger; Robyn Haines; Stefan Niewiesk; Patrick L Green
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Induction of cell cycle arrest by human T-cell lymphotropic virus type 1 Tax in hematopoietic progenitor (CD34+) cells: modulation of p21cip1/waf1 and p27kip1 expression.

Authors:  Adam Tripp; Prabal Banerjee; Michelle Sieburg; Vicente Planelles; Fengzhi Li; Gerold Feuer
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Complete sequence of a novel highly divergent simian T-cell lymphotropic virus from wild-caught red-capped mangabeys (Cercocebus torquatus) from Cameroon: a new primate T-lymphotropic virus type 3 subtype.

Authors:  Laurent Meertens; Renaud Mahieux; Philippe Mauclère; John Lewis; Antoine Gessain
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Authors:  Giovanna Tosi; Elisabetta Pilotti; Lorenzo Mortara; Andrea De Lerma Barbaro; Claudio Casoli; Roberto S Accolla
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

7.  Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.

Authors:  Marilène Halin; Estelle Douceron; Isabelle Clerc; Chloé Journo; Nga Ling Ko; Sébastien Landry; Edward L Murphy; Antoine Gessain; Isabelle Lemasson; Jean-Michel Mesnard; Benoît Barbeau; Renaud Mahieux
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

8.  Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle.

Authors:  Meihong Liu; Liangpeng Yang; Ling Zhang; Baoying Liu; Randall Merling; Zheng Xia; Chou-Zen Giam
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

9.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax oncoproteins modulate cell cycle progression and apoptosis.

Authors:  Michelle Sieburg; Adam Tripp; Jung-Woo Ma; Gerold Feuer
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Tax and overlapping rex sequences do not confer the distinct transformation tropisms of human T-cell leukemia virus types 1 and 2.

Authors:  Jianxin Ye; Li Xie; Patrick L Green
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.